"Located on the main campus of University Hospitals Cleveland Medical Center in Cleveland, Ohio, UH Seidman Cancer Center opened in spring 2011. The 375,000-square-foot hospital houses all of our cancer services under one roof to optimize patient- and family-centered care, provide the latest therapies, enhance collaboration and promote clinical research and education. With some of the most advanced technology available, dedicated and skilled clinicians, and participation in hundreds of clinical trials, UH Seidman Cancer Center is a leading resource in the nation in the fight against cancer, and consistently ranks among the top cancer centers in the country out of more than 5,000 hospitals, according to U.S. News & World Report."

During the past decade, Ireland Cancer Center conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 23 clinical trials were completed, i.e. on average, 57.5% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 9 clinical trials were completed. i.e. 81.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ireland Cancer Center" #1 sponsor was "Gynecologic Oncology Group" with 42 trials, followed by "Radiation Therapy Oncology Group" with 40 trials sponsored, "Eastern Cooperative Oncology Group" with 33 trials sponsored, "Children's Oncology Group" with 26 trials sponsored and "Case Comprehensive Cancer Center" with 26 trials sponsored. Other sponsors include 112 different institutions and companies that sponsored additional 78 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ireland Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 187 trials as a collaborator, "Eastern Cooperative Oncology Group" with 13 trials as a collaborator, "SWOG Cancer Research Network" with 8 trials as a collaborator, "North Central Cancer Treatment Group" with 6 trials as a collaborator and "Cancer and Leukemia Group B" with 5 trials as a collaborator. Other collaborators include 59 different institutions and companies that were collaborators in the rest 47 trials.

According to Clinical.Site data, the most researched conditions in "Ireland Cancer Center" are "Leukemia" (25 trials), "Ovarian Cancer" (21 trials), "Breast Cancer" (19 trials), "Lung Cancer" (19 trials) and "Sarcoma" (19 trials). Many other conditions were trialed in "Ireland Cancer Center" in a lesser frequency.

Most popular intervention types in "Ireland Cancer Center" are "Drug" (227 trials), "Radiation" (73 trials), "Biological" (64 trials), "Procedure" (57 trials) and "Other" (15 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (53 trials), "cisplatin" (40 trials), "paclitaxel" (36 trials), "filgrastim" (31 trials) and "cyclophosphamide" (26 trials). Other intervention names were less common.

The vast majority of trials in "Ireland Cancer Center" are 199 trials for "All" genders, 59 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are NaN active trials in "Ireland Cancer Center". 1 are not yet recruiting, 16 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 205 completed trials in Ireland Cancer Center, 1 suspended trials, and 29 terminated clinical trials to date.

Out of the total trials that were conducted in Ireland Cancer Center, 53 "Phase 1" clinical trials were conducted, 149 "Phase 2" clinical trials and 79 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 10 trials that are defined as “Not Applicable".